Trilaciclib: Experimental Treatment for Small-Cell Lung Cancer (SCLC)

Scientific rationale and therapeutic potential

Trilaciclib is a short-acting CDK4/6 inhibitor given as an intravenous infusion prior to chemotherapy. Trilaciclib is designed to:

Clinical results (see: Publications)

Trilaciclib has potential in small-cell lung cancer (SCLC) based on:

G1's ongoing Phase 2 trials in SCLC

G1T28-02 Trial G1T28-03 Trial G1T28-05 Trial
  • first-line, extensive-stage SCLC
  • multi-center, randomized, placebo-controlled
  • carboplatin and etoposide +/- trilaciclib
  • approximately 90 patients
  • no longer enrolling
  • ClinicalTrials.gov identifier: NCT02499770
  • previously treated SCLC
  • multi-center, randomized, placebo-controlled
  • topotecan +/- trilaciclib
  • approximately 120 patients
  • no longer enrolling
  • ClinicalTrials.gov identifier: NCT02514447
  • first-line, extensive-stage SCLC
  • multi-center, randomized, placebo-controlled
  • carboplatin/etoposide + atezolizumab +/- trilaciclib
  • approximately 100 patients
  • no longer enrolling
  • ClinicalTrials.gov identifier: NCT03041311


Click here for printable version of our trilaciclib SCLC clinical trials fact sheet